Vimarsana
Biggest News Aggregation in the World

Page 3 - Zack Gray News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Zack Gray. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Zack Gray Today - Breaking & Trending Today

New Research Finds Telehealth to be a Safe and Effective Option For Those Undergoing Addiction Treatment in the Fentanyl Era - Vimarsana News

New Research Finds Telehealth to be a Safe and Effective Option For Those Undergoing Addiction Treatment in the Fentanyl Era

Data encompassing 200+ patients initiating treatment with telehealth services shows that over 90% returned for their second appointment and over 80% engaged in...

Ophelia Applauds the DEA's Extension on Flexibilities - Vimarsana News

Ophelia Applauds the DEA's Extension on Flexibilities

/PRNewswire/ -- Opioid addiction treatment provider Ophelia applauds the DEA's "Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of...

DEA mum on proposed rule changes that could impact millions of telehealth users seeking prescription drugs - Vimarsana News

DEA mum on proposed rule changes that could impact millions of telehealth users seeking prescription drugs

Telehealth providers say the Biden administration should reconsider proposed regulations that would make obtaining prescription controlled drugs harder.

Source: whyy.org
Synymata Drops 2 Euphoric Singles, "Running" & "You Hurt Me" - Vimarsana News

Synymata Drops 2 Euphoric Singles, "Running" & "You Hurt Me"

With pure emotion and creativity showcased in his music throughout his career, Synymata continues to take listeners on a uplifting journey with

Study: More OUD Patients Stay in Treatment When Offered Buprenorphine via Telemedicine - Vimarsana News

Study: More OUD Patients Stay in Treatment When Offered Buprenorphine via Telemedicine

Patients with opioid use disorder are more likely to stick with their treatment plan when offered buprenorphine via telemedicine, according to a new study. The study involved 1,378 patients, and their 180-day treatment retention rate was 56.4%.